Skip to main content

Table 2 Mutations in QRDR of GyrA and ParC observed in 35 nalidixic acid- and/or ciprofloxacin-resistant S. Typhi isolated between 2002 and 2013 and corresponding zone diameters obtained by the disk diffusion test for ciprofloxacin

From: Antimicrobial susceptibility of travel-related Salmonella enterica serovar Typhi isolates detected in Switzerland (2002–2013) and molecular characterization of quinolone resistant isolates

 

Mutation

   

No. of isolates (%)

GyrA

ParC

No. of CIP resistant isolates (zone diameters [mm])a

Years of isolation

Identified associated country (no. of isolates)

8 (22.9)

Ser83 → Tyr

 

4 (20)

2002–2009

India (2), Bangladesh (1)

18 (51.4)

Ser83 → Phe

 

5 (19–21)

2003–2011

India (2), Pakistan (3), Bangladesh (1), Cambodia (1)

1 (2.9)

Ser83 → Phe

Glu84 → Gly

1 (14)

2006

India (1)

1 (2.9)

Ser83 → Phe

Glu84 → Lys

0 (21)

2008

India (1)

7 (20)

Ser83 → Phe / Asp87 → Asn

Ser80 → Ile

7 (6–11)

2010–2013

India (2), Nepal (1)

  1. Abbreviation: CIP, ciprofloxacin
  2. aBreakpoints for ciprofloxacin according to CLSI guidelines (16): susceptible, ≥30 mm; intermediate, 21–30 mm; resistant, ≤20 mm